Palatin Technologies, Inc. (PTN) announced encouraging results from its phase IIb BREAKOUT study on Thursday. This investigation focused on Bremelanotide, a treatment for patients with diagnosed Type 2 diabetic nephropathy, which is the predominant form of chronic kidney disease.
After six months, 71% of the study's participants experienced a reduction of more than 30% in their urine protein to creatinine ratio. Additionally, an equal percentage of participants either saw improvements in or maintained stability in their estimated glomerular filtration rate.
Moreover, the therapy was found to increase urinary vascular endothelial growth factor levels in 37.5% of those involved, while it also led to a reduction in urinary synaptopodin losses in 36% of participants.
Before the market opened, Palatin's shares were trading at $0.78 on the New York Stock Exchange, a 4.37% increase.
The material has been provided by InstaForex Company - www.instaforex.com
After six months, 71% of the study's participants experienced a reduction of more than 30% in their urine protein to creatinine ratio. Additionally, an equal percentage of participants either saw improvements in or maintained stability in their estimated glomerular filtration rate.
Moreover, the therapy was found to increase urinary vascular endothelial growth factor levels in 37.5% of those involved, while it also led to a reduction in urinary synaptopodin losses in 36% of participants.
Before the market opened, Palatin's shares were trading at $0.78 on the New York Stock Exchange, a 4.37% increase.
The material has been provided by InstaForex Company - www.instaforex.com